Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Drug Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy N/A

    Medical Drugs Not Eligible for Reimbursement

    Customize your policy alerts

    Sign up for all Bluecross Idaho policy alerts

    Know when Bluecross Idaho releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy identifies pharmacologic therapies and related technologies that are not eligible for reimbursement under the medical benefit, including pharmacy-benefit-only drugs, FDA-unapproved or unauthorized drugs, experimental/investigational technologies, and drugs designated not medically necessary. Coverage remains subject to the member-specific benefit plan, applicable law, and related Blue Cross of Idaho policies.

    Policy Summary
    PayerBluecross Idaho
    PolicyMedical Drugs Not Eligible for Reimbursement
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewJul 30, 2026
    Next Review DateN/A
    Key ActionBefore applying the policy, verify member eligibility, the member-specific benefit plan, and the date of service.
    SourceLink
    POLICY UPDATE CHANGES

    The policy tables include newly added medical-drug codes and products, including additions dated in 2026.

    The policy distinguishes pharmacy-benefit-only drugs, experimental/investigational drugs, and drugs that are not medically necessary as separate categories of medical-benefit noncoverage.

    The policy was revised to clarify statements about oral medications billed under major medical benefits.

    Drug codes were added to Table 1 Pharmacy Benefit Medications Only and Table 3 Not Medically Necessary.

    Drug codes were deleted from Table 2 Experimental/Investigational Codes.

    The policy history records prior additions and removals of codes in Tables 1 and 3 and updates to Table 3 codes.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3Noncovered code tables
    16HCPCS drug codes listed
    5Investigational-technology criteria
    Medical benefitBenefit domain
    RequiredFDA/P&T review
    5Potentially excluded lines of business

    Medical-Benefit Coverage Criteria

    General medical-benefit exclusions

    Not eligible under the medical benefit when any applicable condition is met.

    General nonreimbursement conditions

    • The medication is not approved or authorized for use by the FDA or HHS, or the authorization has been removed, including when an FDA approval has been revoked or an EUA has ended.
    • The medication is newly approved or issued an EUA by the FDA but has not yet been reviewed and implemented by Blue Cross of Idaho's Pharmacy and Therapeutics Committee.
    • The medication is authorized only for inpatient use but is billed at an outpatient clinic or facility.
    • The technology is determined to be experimental or investigational under the applicable Blue Cross of Idaho criteria.

    Oral medications billed under major medical

    Major medical benefits may apply when any listed condition is met.

    Oral medication billing criteria

    • The drug is billed by a hospital, surgery center, or dialysis provider in conjunction with other services, such as chemotherapy, surgery, or diagnostic procedures.
    • The prescription drug benefit is integrated into the major medical benefit.

    Listed noncovered drugs

    A listed drug is not eligible for reimbursement under the medical benefit when any applicable table category applies.

    Table-specific noncoverage categories

    • The drug is listed in Table 1 as covered only under the pharmacy benefit and is billed under the medical benefit.
    • The drug is listed in Table 2 as experimental or investigational.
    • The drug is listed in Table 3 as not medically necessary because it is cost prohibitive or more cost-effective options are available.

    Contract exclusions are outside the scope of this medical policy. Apply the member’s contract and applicable benefit provisions when evaluating coverage.

    Medications authorized only for inpatient use are not eligible for reimbursement under the medical benefit when billed by outpatient clinics or facilities.

    This policy may not apply to all lines of business, including the Federal Employee Program, Medicare Supplement, Medicare Advantage, Medicaid, and certain self-insured groups. Confirm the applicable member benefit before applying the policy.

    The pharmacologic therapies identified by this policy are not eligible for reimbursement under the medical benefit. Coverage determinations remain subject to the applicable member benefit plan and related policy requirements.

    Drugs listed in Table 3 are considered not medically necessary and are not eligible for reimbursement under the medical benefit because they are cost prohibitive or more cost-effective options are available.

    Noncovered Drug Code Tables

    Table 1. Pharmacy Benefit Medications OnlyHCPCSNot Covered
    C9818Suzetrigine, oral, 1 mg
    J0139Injection, adalimumab, 1 mg
    J0224Injection, lumasiran, 0.5 mg (Oxlumo)
    J0401Injection, aripiprazole (Abilify Maintena), 1 mg
    J0517Injection, benralizumab, 1 mg (Fasenra)
    J0571Buprenorphine, oral, 1 mg
    J0572Buprenorphine/naloxone, oral, less than or equal to 3 mg
    J0573Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg
    J0574Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg
    J0575Buprenorphine/naloxone, oral, greater than 10 mg
    1–10 of 67
    1/7
    Table 2. Experimental/Investigational CodesHCPCSExperimental
    J0174Injection, lecanemab-irmb, for intravenous injection 1 mg (Leqembi)
    J0175Injection, donanemab-azbt, 2 mg (Kisunla)
    J1413Injection, delandistrogene moxeparvovec-rokl (Elevidys)
    J2267Injection, mirikizumab-mrkz, 1 mg (Omvoh)
    J2779Injection, ranibizumab, via intravitreal implant (Susvimo), 0.1 mg
    J7314Injection, fluocinolone acetonide, intravitreal implant (Yutiq), 0.01
    Table 3. Not medically necessaryHCPCSNot Covered
    J1072Injection, testosterone cypionate (Azmiro), 1 mg
    J1305Injection, evinacumab-dgnb (Evkeeza), 5 mg
    J1552Injection, immune globulin (Alyglo), 500 mg
    J1554Injection, immune globin (Asceniv), 500 mg
    J2428Injection, paliperidone palmitate extended release (Erzofri), 1 mg
    J3145Injection, testosterone undecanoate, 1 mg (Aveed)
    J9183Gemcitabine intravesical system, 225 mg
    Q5098Injection, ustekinumab-srlf (Imuldosa), biosimilar, 1 mg
    Q5099Injection, ustekinumab-stba (Steqeyma), biosimilar, 1 mg
    Q5137Injection, ustekinumab-auub (Wezlana), biosimilar, subcutaneous, 1 mg
    1–10 of 30
    1/3
    Table 1 Pharmacy Benefit Medications OnlyHCPCSNot Covered
    Q5153Injection, aflibercept-yszy (Opuviz), biosimilar, 1 mg.
    Q5155Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg.
    Q5156Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg.
    Q5158Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg.
    Q5159Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg.
    Q5164Injection, ustekinumab-hmny, biosimilar, 1 mg (SQ or IV).
    Q5165Injection, denosumab-mobz (Oziltus), biosimilar, 1 mg.
    Q5166Injection, denosumab-desu (Osvyrti/Jubereq), biosimilar, 1 mg.
    Q5167Injection, denosumab-qbde (Enoby/Xtrenbo), biosimilar, 1 mg.
    Q5168Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg.
    1–10 of 16
    1/2

    Provider Billing and Review Actions

    Note

    Portal Result Does Not Establish Coverage

    Do not treat a Provider portal result of “no prior authorization required” as confirmation that a drug is covered. The listed codes may be noncovered or investigational; review the applicable benefit and policy provisions before billing or advising the member.

    Documentation Required

    Route Uncertain Oral-Drug Claims

    Route uncertain oral medication claims or coverage questions to PM for review before billing or making a coverage determination.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Policy Background

    This policy is primarily an administrative and benefit-eligibility policy, rather than a condition-specific clinical policy. It identifies pharmacologic therapies and related technologies that are not eligible for reimbursement under the medical benefit, including pharmacy-benefit-only drugs, unauthorized or unapproved drugs, experimental or investigational technologies, and drugs designated not medically necessary.

    Key Definitions

    Investigational technology
    DefinitionA service, supply, procedure, treatment, drug, device, facility, equipment, or biological product in a developmental stage or not proven to improve health outcomes.
    Regulatory approvalThe technology must have final approval from the appropriate government regulatory body for the condition being evaluated; interim approval is not enough.
    Scientific evidenceCurrent published medical literature and peer-reviewed investigations must permit conclusions about the technology’s effects on health outcomes.
    Net health outcomeThe technology’s beneficial effects on health outcomes must outweigh harmful effects.
    Established alternativesThe technology must be as beneficial as established alternatives.
    Usual medical practiceImprovement must be attainable outside the investigational setting under usual conditions of medical practice.

    Site-of-Care Billing Rules

    Billing Rule

    Do not bill inpatient-only medications as hospital outpatient

    Medications authorized only for inpatient use are not eligible for reimbursement when billed at outpatient clinics or facilities. Confirm the medication’s authorized setting before submitting a hospital outpatient claim.

    Corresponding Biologic Reference Drugs

    Billing Rule

    Check listed biosimilars against the applicable table

    Identify biosimilars listed in the applicable table and do not submit them for reimbursement under the medical benefit. The listed biosimilars are not eligible for medical-benefit reimbursement; this policy does not state a preferred biosimilar.

    Policy Summary
    PayerBluecross Idaho
    PolicyMedical Drugs Not Eligible for Reimbursement
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateNov 1, 2026
    Last ReviewJul 30, 2026
    Next Review DateN/A
    Key ActionBefore applying the policy, verify member eligibility, the member-specific benefit plan, and the date of service.
    SourceLink
    On This Page
    Medical-Benefit Coverage CriteriaNoncovered Drug Code TablesProvider Billing and Review ActionsPolicy BackgroundKey DefinitionsSite-of-Care Billing RulesCorresponding Biologic Reference Drugs
    Billing Rule

    Confirm FDA Authorization and P&T Implementation

    Before billing a pharmacologic therapy, confirm its FDA or HHS authorization status and whether Blue Cross of Idaho’s Pharmacy and Therapeutics Committee has reviewed and implemented coverage for newly approved or emergency-use-authorized therapies.

    • Medications without required authorization, with authorization removed, or with ended emergency use authorization are not eligible for reimbursement.
    • Newly FDA-approved or EUA therapies are not eligible under the medical benefit until reviewed and implemented by the P&T Committee.
    Denial Risk

    Experimental or Investigational Technology

    Identify services, therapies, supplies, drugs, devices, facilities, equipment, or biological products that meet Blue Cross of Idaho’s experimental or investigational definition. Such technologies are not eligible for reimbursement under this policy.

    • Final approval from the appropriate governmental regulatory body is required; interim approval is not sufficient.
    • The evidence must support improved net health outcomes, benefit at least as much as established alternatives, and demonstrate improvement under usual conditions of medical practice.
    Billing Rule

    Use the Correct Benefit and Billing Site

    Apply the correct benefit and billing site. Inpatient-only medications are not eligible when billed by outpatient clinics or facilities; oral prescription drugs may be subject to the prescription drug benefit rather than the medical benefit.

    • Major medical coverage for oral medications may apply when billed by a hospital, surgery center, or dialysis provider in conjunction with services such as chemotherapy, surgery, or diagnostic procedures.
    • If prescription drug benefits are not included under major medical, deny as noncovered. If a third-party pharmacy benefit manager administers the benefit, deny under major medical unless an exception has been granted.
    Denial Risk

    Not Medically Necessary

    Do not bill listed Table 3 drugs as covered under the medical benefit. These drugs are considered not medically necessary and are not eligible for reimbursement because they are cost prohibitive or more cost-effective alternatives are available.

    • Consult MP 5.01.500 for preferred and non-preferred medical drug information.
    Denial Risk

    Medical-Benefit Billing for Listed Drugs

    Claims may be denied when listed pharmacologic therapies are submitted under the medical benefit, including therapies identified as pharmacy-benefit-only, experimental or investigational, or not medically necessary.

    • Confirm whether the drug belongs under the pharmacy benefit before submitting a medical-benefit claim.
    • A portal response of “no prior authorization required” does not override a noncoverage determination.
    Medically necessary
    DefinitionA covered service or supply required to identify or treat an insured’s condition, disease, illness, or accidental injury, as recommended by the treating physician or other covered provider and determined by Blue Cross of Idaho.
    Appropriate level of serviceThe service or supply is the most appropriate level of service, considering potential benefits and harms to the insured.
    EffectivenessThe service or supply is proven to improve health outcomes; for new treatments, effectiveness is determined by scientific evidence.
    Existing-treatment standardsFor existing treatments, effectiveness is determined first by scientific evidence, then by professional standards, and then by expert opinion.
    ConvenienceThe service or supply is not primarily for the convenience of the insured or covered provider.
    Cost-effectivenessThe service or supply is cost-effective compared with alternative treatments, including no treatment; cost-effective does not necessarily mean lowest price.